29. Februar 2016 von

DGAP-News: Formycon AG: Formycon discloses details on second pipeline product – FYB203 is a biosimilar for Eylea (aflibercept)

Formycon AG: DGAP-News: Formycon AG / Key word(s): Research Update/Study Formycon AG: Formycon discloses details on second pipeline product – FYB203 is a biosimilar for Eylea (aflibercept) 29.02.2016 / 08:00 The issuer is solely responsible for the content …

Das könnte Sie interessieren

  1. DGAP-News: Formycon AG: Formycon veröffentlicht Details zu weiterem Pipelineprodukt – FYB203 ist ein Biosimilar-Kandidat für Eylea (Aflibercept)
  2. DGAP-News: Formycon AG: Formycon and bioeq enroll first patient in pivotal phase III study with biosimilar ranibizumab (FYB201)
  3. DGAP-News: Formycon AG: Formycon ends 2015 fiscal year with successful results

Comments are closed.